⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BLTE News
Belite Bio, Inc American Depositary Shares
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
globenewswire.com
BLTE
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
globenewswire.com
BLTE
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight
globenewswire.com
JNJ
OCGN
APLS
ALXN
IONS
BLTE
LCTX
REGN
AVNX
NBIX
STE
COG
AVD
OCUGEN
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
globenewswire.com
BLTE
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
globenewswire.com
BLTE
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
globenewswire.com
BLTE
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
globenewswire.com
BLTE
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
globenewswire.com
BLTE
Belite Bio to Participate in the 2025 Maxim Growth Summit
globenewswire.com
BLTE
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
globenewswire.com
BLTE